eyeTube in Combination With the eyeWatch Implant

Inclusion Criteria: * \- Men and women aged 18 to 85. * Diagnosis of primary open-angle glaucoma meeting both of the following criteria: * IOP uncontrolled by at least one (1) or more classes of topical IOP-lowering medical therapy, and * Failure of at least one (1) conventional intraocular glaucoma surgery (e.g., glaucoma filter surgery or tube shunting) or cilioablative procedures (e.g., cryotherapy, cyclodiode therapy). * Trabecular meshwork visible on gonioscopy, with a Shaffer angle ≥ 3 in the target quadrant. * Patients must be able to understand the study requirements and provide written informed consent. * Patients must be willing to follow study instructions, agree to comply with all study procedures and be able to attend all scheduled follow-up examinations for at least 12 months after surgery. Exclusion Criteria: * \- Previous filtering surgery, secondary glaucoma, severe systemic disease, pregnancy, breast-feeding, inability to understand or give informed consent. * Choroidal detachment, choroidal effusion or any active choroidopathy. * Diagnosis of acute angle-closure glaucoma or malignant glaucoma. * History of glaucoma drainage/valve implant in target quadrant * Presence of conjunctival scarring, previous conjunctival surgery or other conjunctival pathology (e.g. pterygium) in the target quadrant. * Use of systemic (oral or intravenous) glaucoma medications * History of corneal surgery (including LASIK and PRK), corneal opacities, corneal diseases or any corneal pathology likely to interfere with IOP measurement. * Eyes with ocular malformations such as microphthalmia * Eyes with concomitant inflammatory/infectious ocular disorders * Aphakia * Presence of an anterior chamber intraocular lens or implantable contact lens * Previous complicated cataract surgery or presence of vitreous in the anterior chamber * Cataract surgery performed less than 6 months before the start of the study * Presence of intraocular silicone oil * Previous diagnosis of chronic uveitis in either eye * Active diabetic retinopathy, choroidal neovascularization, secondary retinal vein occlusion, central retinal vein occlusion, proliferative retinopathy or other ophthalmic disease or disorder likely to distort study results. * Impaired episcleral venous drainage (e.g., Sturge-Weber or nanophthalmos or other evidence of elevated venous pressure) * Uncontrolled systemic disease (e.g. diabetes, hypertension) * History of dermatological keloid formation * Use of ocular or systemic steroids in the last 30 days (chronic continuous use of systemic steroids is permitted) prior to the screening visit, or known response to corticosteroids. * Pregnant or breast-feeding women, or women of childbearing age who do not wish to use medically acceptable contraception between the screening visit and the 12-month follow-up visit. * Known or suspected allergy or hypersensitivity to any component of the device (e.g. silicone). * Current participation or participation within the last 30 days (from the screening visit) in another clinical trial of an investigational drug or interventional device.